MediWound (NASDAQ:MDWD – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.
Insider & Institutional Ownership
46.8% of MediWound shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 15.0% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares MediWound and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -180.30% | -67.22% | -31.87% |
| Journey Medical | -14.82% | -35.57% | -10.88% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 1 | 2 | 0 | 2.25 |
| Journey Medical | 1 | 1 | 2 | 0 | 2.25 |
MediWound presently has a consensus price target of $34.00, suggesting a potential upside of 135.29%. Journey Medical has a consensus price target of $13.00, suggesting a potential upside of 109.00%. Given MediWound’s higher possible upside, analysts clearly believe MediWound is more favorable than Journey Medical.
Volatility & Risk
MediWound has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
Earnings & Valuation
This table compares MediWound and Journey Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $16.96 million | 10.95 | -$23.88 million | ($2.26) | -6.39 |
| Journey Medical | $64.68 million | 2.65 | -$11.43 million | ($0.37) | -16.81 |
Journey Medical has higher revenue and earnings than MediWound. Journey Medical is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
Summary
Journey Medical beats MediWound on 8 of the 12 factors compared between the two stocks.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
